Examples include Ozempic, Wegovy and Mounjaro
The BDNF evidence includes preclinical studies showing a 1.4-fold increase in hippocampal BDNF protein and a 3-fold increase in BDNF mRNA expression following a single dose, and a human stroke trial in 110 patients where intranasal Semax produced measurable plasma BDNF elevation associated with improved motor function recovery
Risks and who should avoid it Because GLP-1 microdosing exists entirely outside of FDA-approved guidelines, there is currently no clinical trial data establishing its safety or efficacy
Those are pharmacology results, not proof of a clinical benefit there is no controlled human trial showing CJC-1295 improves body composition, a disease outcome, or any functional measure, and the no-DAC form has no controlled human trials at all
In case of any alarming symptoms during the use of peptides, immediate consultation with a doctor is necessary
Acitretin in psoriasis: an overview of adverse effects